Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020

키워드

참고문헌 (207)

1. Hunt RH, "Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline", J Gastrointestin Liver Dis, 20, pp.299~304 (2011)
2. Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)
3. Malfertheiner P, "Peptic ulcer disease", Lancet, 374, pp.1449~1461 (2009)
4. Fock KM, "Helicobacter pylori research : historical insights and future directions", Nat Rev Gastroenterol Hepatol, 10, pp.495~500 (2013)
5. "Vital Statistics of Korea PeriodAnnual 1970–2018" (2019)[URL]
6. Asaka M, "Guidelines for the management of Helicobacter pylori infection in Japan : 2009revised edition", Helicobacter, 15, pp.1~20 (2010)
7. Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
8. Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
9. Braden B, "The best and worst treatments for Helicobacter pylori", BMJ, 351, pp.h4146~ (2015)
10. De Francesco V, "Worldwide H. pylori antibiotic resistance : a systematic review", J Gastrointestin Liver Dis, 19, pp.409~414 (2010)
11. Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
12. Kim JM, "Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea", Antimicrob Agents Chemother, 48, pp.4843~4847 (2004)
13. Hwang TJ, "Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea", J Clin Gastroenterol, 44, pp.536~543 (2010)
14. Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
15. Glasier A, "A consensus process to adapt the World Health Organization selected practice recommendations for UK use", Contraception, 68, pp.327~333 (2003)
16. Higgins JP, "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
17. Kim SY, "Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity", J Clin Epidemiol, 66, pp.408~414 (2013)
18. Schünemann H, "GRADE handbook" (2013), The Cochrane Collaboration
19. Andrews J, "GRADE guidelines : 14. Going from evidence to recommendations : the significance and presentation of recommendations", J Clin Epidemiol, 66, pp.719~725 (2013)
20. Cho JH, "Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients", J Gastroenterol Hepatol, 34, pp.700~706 (2019)
21. Tae-Geun Gweon, "An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment", Gut and Liver, 12(6), pp.648~654 (2018), 거트앤리버 소화기연관학회협의회
22. Jones J, "Consensus methods for medical and health services research", BMJ, 311, pp.376~380 (1995)
23. McLean E, "Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005", Public Health Nutr, 12, pp.444~454 (2009)
24. Stevens GA, "Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011 : a systematic analysis of population-representative data", Lancet Glob Health, 1, pp.e16~ (2013)
25. Zhang ZW, "The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach", Gut, 43, pp.322~326 (1998)
26. Calam J, "How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology", Gastroenterology, 113(6Suppl), pp.S43~S49 (1997)
27. Hudak L, "An updated systematic review and meta-analysis on the association between Helicobacter pylori infection and iron deficiency anemia", Helicobacter, 22, pp.e12330~ (2017)
28. Chen LH, "Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis", World J Gastroenterol, 13, pp.5380~5383 (2007)
29. Miernyk K, "The effect of Helicobacter pylori infection on iron stores and iron deficiency in urban Alaska Native adults", Helicobacter, 18, pp.222~228 (2013)
30. Monzón H, "Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin", World J Gastroenterol, 19, pp.4166~4171 (2013)
31. Choi IJ, "Helicobacter pylori therapy for the prevention of metachronous gastric cancer", N Engl J Med, 378, pp.1085~1095 (2018)
32. Fukase K, "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomized controlled trial", Lancet, 372, pp.392~397 (2008)
33. Choi JM, "Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention : a randomized controlled trial", Gastrointest Endosc, 88, pp.475~485 (2018)
34. 송지현, "헬리코박터 파일로리 제균 치료가 위 이형성의 내시경 절제술 후 이시성 재발에 미치는 영향", 대한소화기학회지, 70(1), pp.27~32 (2017), 대한소화기학회
35. Shin SH, "Helicobacter pylori eradication prevents metachronous gastric neoplasms after endoscopic resection of gastric dysplasia", PLoS One, 10, pp.e0143257~ (2015)
36. 전일영, "Effect of Helicobacter pylori Eradication on Subsequent Dysplasia Development after Endoscopic Resection of Gastric Dysplasia", 대한소화기학회지, 61(6), pp.307~312 (2013), 대한소화기학회
37. Du LJ, "Helicobacter pylori eradication therapy for functional dyspepsia : systematic review and meta-analysis", World J Gastroenterol, 22, pp.3486~3495 (2016)
38. Zhao B, "Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia : a metaanalysis of randomized controlled studies with 12-month follow-up", J Clin Gastroenterol, 48, pp.241~247 (2014)
39. Moayyedi P, "ACG and CAG clinical guideline : management of dyspepsia", Am J Gastroenterol, 112, pp.988~1013 (2017)
40. McColl K, "Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia", N Engl J Med, 339, pp.1869~1874 (1998)
41. Blum AL, "Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment(OCAY)Study Group", N Engl J Med, 339, pp.1875~1881 (1998)
42. Talley NJ, "Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia", N Engl J Med, 341, pp.1106~1111 (1999)
43. Talley NJ, "Eradication of Helicobacter pylori in functional dyspepsia : randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia(ORCHID)Study Group", BMJ, 318, pp.833~837 (1999)
44. Koskenpato J, "Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia", Am J Gastroenterol, 96, pp.2866~2872 (2001)
45. Hsu PI, "Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia", Aliment Pharmacol Ther, 15, pp.195~201 (2001)
46. Bruley Des Varannes S, "There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia", Aliment Pharmacol Ther, 15, pp.1177~1185 (2001)
47. Froehlich F, "Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia", Am J Gastroenterol, 96, pp.2329~2336 (2001)
48. Chiba N, "Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia : the Canadian adult dyspepsia empiric treatment. Helicobacter pylori positive(CADET-Hp)randomised controlled trial", BMJ, 324, pp.1012~1016 (2002)
49. Veldhuyzen van Zanten S, "Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional(nonulcer)dyspepsia", Am J Gastroenterol, 98, pp.1963~1969 (2003)
50. Malfertheiner P, "Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia", Aliment Pharmacol Ther, 18, pp.615~625 (2003)
51. Gisbert JP, "Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia : randomized one-year follow-up study", Hepatogastroenterology, 51, pp.303~308 (2004)
52. Mazzoleni LE, "Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : results of a 12-month randomized, double blind, placebo-controlled study", Dig Dis Sci, 51, pp.89~98 (2006)
53. Ang TL, "Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia : a randomized, double-blind study", J Gastroenterol, 41, pp.647~653 (2006)
54. Gwee KA, "The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection", Eur J Gastroenterol Hepatol, 21, pp.417~424 (2009)
55. Mazzoleni LE, "Helicobacter pylori eradication in functional dyspepsia : HEROES trial", Arch Intern Med, 171, pp.1929~1936 (2011)
56. Sodhi JS, "Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India", J Gastroenterol Hepatol, 28, pp.808~813 (2013)
57. Yazdanbod A, "Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia : a prospective, randomized, placebo-controlled trial", Arch Med Sci, 11, pp.964~969 (2015)
58. Kang SJ, "Helicobacter pylori eradication therapy for functional dyspepsia : a meta-analysis by region and H. pylori prevalence", J Clin Med, 8, pp.1324~ (2019)
59. Hooi JKY, "Global prevalence of Helicobacter pylori infection : systematic review and metaanalysis", Gastroenterology, 153, pp.420~429 (2017)
60. Chen HN, "Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia : evidence from a meta-analysis", Gastric Cancer, 19, pp.166~175 (2016)
61. Rokkas T, "A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer", Ann Gastroenterol, 30, pp.414~423 (2017)
62. Yanaoka K, "Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels", Int J Cancer, 125, pp.2697~2703 (2009)
63. Li WQ, "Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups", J Natl Cancer Inst, 106, pp.dju116~ (2014)
64. Fallone CA, "The Toronto consensus for the treatment of Helicobacter pylori infection in adults", Gastroenterology, 151, pp.51~69 (2016)
65. Choi HS, "Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate", Helicobacter, 12, pp.638~642 (2007)
66. Kim BG, "Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication : neither treatment duration provides acceptable eradication rate in Korea", Helicobacter, 12, pp.31~35 (2007)
67. Kim SY, "Comparative study of Helicobacter pylori eradication rates of twice-versus four-timesdaily amoxicillin administered with proton pump inhibitor and clarithromycin : a randomized study", Helicobacter, 13, pp.282~287 (2008)
68. Kim N, "Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea", Helicobacter, 13, pp.542~549 (2008)
69. 최우혁, "Helicobacter pylori 감염 환자에서 10일 연속 제균치료의 효과", 대한소화기학회지, 51(5), pp.280~284 (2008), 대한소화기학회
70. Kim MN, "The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication", Helicobacter, 13, pp.261~268 (2008)
71. 정지민, "소화성 궤양 치료에서 Helicobacter pylori 제균 삼제 요법과 추가적인 위산분비 억제치료의 역할", 대한소화기학회지, 51(1), pp.11~18 (2008), 대한소화기학회
72. Kim HW, "H pylori eradication : a randomized prospective study of triple therapy with or without ecabet sodium", World J Gastroenterol, 14, pp.908~912 (2008)
73. Jeong Hoon Lee, "The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole", Gut and Liver, 4(2), pp.201~206 (2010), 거트앤리버 소화기연관학회협의회
74. Song MJ, "The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori", Helicobacter, 15, pp.206~213 (2010)
75. Kim YS, "Randomised clinical trial : the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea", Aliment Pharmacol Ther, 34, pp.1098~1105 (2011)
76. 최강현, "Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial", Journal of Korean Medical Science, 26(6), pp.785~790 (2011), 대한의학회
77. Chung JW, "Ten-day sequential versus triple therapy for Helicobacterpylori eradication : a prospective, open-label, randomized trial", J Gastroenterol Hepatol, 27, pp.1675~1680 (2012)
78. Choi HS, "Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection", World J Gastroenterol, 18, pp.2377~2382 (2012)
79. Park HG, "Randomised clinical trial : a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients", Aliment Pharmacol Ther, 35, pp.56~65 (2012)
80. Oh HS, "Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea : a prospective, randomized study", J Gastroenterol Hepatol, 27, pp.504~509 (2012)
81. Kim SY, "Effectiveness of three times daily lansoprazole", amoxicillin dual therapy for Helicobacter pylori infection in Korea, 2012, pp.73, 140~143
82. Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance", J Infect Dis, 208, pp.1123~1130 (2013)
83. Kim SY, "Comparative study of Helicobacter pylori eradication rates with 5-day quadruple"concomitant"therapy and 7-day standard triple therapy", J Clin Gastroenterol, 47, pp.21~24 (2013)
84. Heo J, "A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication", Dig Liver Dis, 46, pp.980~984 (2014)
85. Park CS, "Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance", Am J Gastroenterol, 109, pp.1595~1602 (2014)
86. Lee JW, "A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea", Scand J Gastroenterol, 49, pp.917~924 (2014)
87. Lee HJ, "Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies", World J Gastroenterol, 21, pp.351~359 (2015)
88. 방창석, "Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection", Gut and Liver, 9(3), pp.340~345 (2015), 거트앤리버 소화기연관학회협의회
89. Chung JW, "Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication : a multicenter, prospective study", Dig Liver Dis, 48, pp.888~892 (2016)
90. 김준성, "Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial", Gut and Liver, 10(4), pp.556~561 (2016), 거트앤리버 소화기연관학회협의회
91. Beom Jin Kim, "Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea", Gut and Liver, 13(5), pp.531~540 (2019), 거트앤리버 소화기연관학회협의회[DOI]
92. Jung YS, "Efficacy of Helicobacter pylori eradication therapies in Korea : a systematic review and network meta-analysis", Helicobacter, 22, pp.e12389~ (2017)
93. Liu WZ, "Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection", Helicobacter, 23, pp.e12475~ (2018)
94. Gao XZ, "Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication", World J Gastroenterol, 16, pp.4357~4362 (2010)
95. Lahbabi M, "Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication : result of the HPFEZ randomized study", Clin Res Hepatol Gastroenterol, 37, pp.416~421 (2013)
96. Rakici H, "Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection : patients' compliance and bacterial eradication rates", J Dig Dis, 15, pp.508~513 (2014)
97. Molina-Infante J, "Clinical trial : clarithromycin vs. levofloxacin in firstline triple and sequential regimens for Helicobacter pylori eradication", Aliment Pharmacol Ther, 31, pp.1077~1084 (2010)
98. Javid G, "Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India : a randomized comparative trial", Indian J Gastroenterol, 32, pp.190~194 (2013)
99. Morse AL, "A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North", Can J Gastroenterol, 27, pp.701~706 (2013)
100. Zhou L, "A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection : a randomized multicenter trial", Am J Gastroenterol, 109, pp.535~541 (2014)
101. Lee H, "Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea", Dig Liver Dis, 47, pp.114~118 (2015)
102. Greenberg ER, "14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites : a randomised trial", Lancet, 378, pp.507~514 (2011)
103. Nasa M, "Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication : a randomized study", Indian J Gastroenterol, 32, pp.392~396 (2013)
104. Boal Carvalho P, "Randomized controlled trial for Helicobacter pylori eradication in a naïve Portuguese population: is sequential treatment superior to triple therapy in real world clinical setting?", Acta Med Port, 30, pp.185~189 (2017)
105. Liou JM, "Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations : a randomised trial", Gut, 65, pp.1784~1792 (2016)
106. Phiphatpatthamaamphan K, "Effect of IL-1 polymorphisms, CYP2C19 genotype and antibiotic resistance on Helicobacter pylori eradication comparing between 10-day sequential therapy and 14-day standard triple therapy with four-times-daily-dosing of amoxicillin in Thailand : a prospective randomized study", Asian Pac J Cancer Prev, 17, pp.1903~1907 (2016)
107. Alsohaibani F, "Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection", Saudi J Gastroenterol, 21, pp.220~225 (2015)
108. Liu KS, "Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients : an open label, randomised, crossover trial", Gut, 63, pp.1410~1415 (2014)
109. Kefeli A, "Comparison of three different regimens against Helicobacter pylori as a first-line treatment : a randomized clinical trial", Bosn J Basic Med Sci, 16, pp.52~57 (2016)
110. Sardarian H, "Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran : a prospective randomized trial", Helicobacter, 18, pp.129~134 (2013)
111. Chen KY, "Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan : a prospective randomized trial", World J Gastroenterol, 21, pp.10435~10442 (2015)
112. Kim SY, "Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea", Helicobacter, 22, pp.e2441~ (2017)
113. Molina-Infante J, "Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance", Gastroenterology, 145, pp.121~128 (2013)
114. Hong J, "Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection : an open-label, randomized, single-centre clinical trial", J Antimicrob Chemother, 71, pp.2280~2285 (2016)
115. Park SM, "Randomized clinical trial comparing 10-or 14-day sequential therapy and 10-or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection", J Gastroenterol Hepatol, 32, pp.589~594 (2017)
116. Liou JM, "Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial", Lancet, 388, pp.2355~2365 (2016)
117. Das R, "Sequential versus concomitant therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer : a randomized trial", Saudi J Gastroenterol, 22, pp.309~315 (2016)
118. Georgopoulos SD, "Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area", Eur J Intern Med, 32, pp.84~90 (2016)
119. Apostolopoulos P, "Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection : a Greek randomized prospective study", Scand J Gastroenterol, 51, pp.145~151 (2016)
120. Zhou L, "Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment : a randomized trial", Helicobacter, 21, pp.91~99 (2016)
121. Gungor G, "Current status of five different regimens for empiric first-line Helicobacter pylori eradication in Turkey", Digestion, 92, pp.55~59 (2015)
122. Heo J, "Concomitant and hybrid therapy for Helicobacter pylori infection : a randomized clinical trial", J Gastroenterol Hepatol, 30, pp.1361~1366 (2015)
123. Cuadrado-Lavín A, "First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori : an open-label, randomized, multicentre clinical trial", J Antimicrob Chemother, 70, pp.2376~2381 (2015)
124. Molina-Infante J, "Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice : the OPTRICON study", Aliment Pharmacol Ther, 41, pp.581~589 (2015)
125. Ang TL, "Ten-day triple therapy versus sequential therapy versus concomitant therapy as firstline treatment for Helicobacter pylori infection", J Gastroenterol Hepatol, 30, pp.1134~1139 (2015)
126. McNicholl AG, "Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice", Gut, 63, pp.244~249 (2014)
127. Lim JH, "Clinical outcomes of twoweek sequential and concomitant therapies for Helicobacter pylori eradication : a randomized pilot study", Helicobacter, 18, pp.180~186 (2013)
128. Georgopoulos S, "Nonbismuth quadruple"concomitant"therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication : a randomized trial", J Clin Gastroenterol, 47, pp.228~232 (2013)
129. Wu DC, "Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection", Clin Gastroenterol Hepatol, 8, pp.36~41 (2010)
130. De Francesco V, "Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication : a prospective, randomized study", Dig Liver Dis, 50, pp.139~141 (2018)
131. De Francesco V, "Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study", J Med Microbiol, 63(Pt 5), pp.748~752 (2014)
132. Huang YK, "Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication", J Dig Dis, 13, pp.232~238 (2012)
133. Molina-Infante J, "Nonbismuth quadruple(concomitant)therapy : empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains", Helicobacter, 17, pp.269~276 (2012)
134. Georgopoulos SD, ""Concomitant" or "sequential" eradication of Helicobacter pylori: which regimen comes first?", Ann Gastroenterol, 27, pp.280~281 (2014)
135. Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use : nationwide survey", Helicobacter, 21, pp.266~278 (2016)
136. 김범진, "Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis", Journal of Korean Medical Science, 31(8), pp.1246~1253 (2016), 대한의학회
137. Wenzhen Y, "Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials", Intern Med, 49, pp.1103~1109 (2010)
138. López-Góngora S, "Systematic review and meta-analysis : susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection", J Antimicrob Chemother, 70, pp.2447~2455 (2015)
139. Chey WD, "ACG clinical guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
140. Li BZ, "Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis", BMJ, 351, pp.h4052~ (2015)
141. Yeo YH, "First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance : a systematic review and network meta-analysis", Gut, 67, pp.20~27 (2018)
142. 정준원, "Meta-analysis: Sequential Therapy Is Superior to Conventional Therapy for Helicobacter pylori Infection in Korea", 대한소화기학회지, 62(5), pp.267~271 (2013), 대한소화기학회
143. Gisbert JP, "Review article : the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough", Aliment Pharmacol Ther, 34, pp.1255~1268 (2011)
144. Wu TS, "Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacinbased triple therapy for Helicobacter pylori", J Dig Dis, 18, pp.537~542 (2017)
145. Munteanu D, "Efficacy and safety of sequential versus quadruple therapy as second-line treatment for Helicobacter pylori infection : a randomized controlled trial", PLoS One, 12, pp.e0183302~ (2017)
146. Mori H, "Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication : a pilot study", United European Gastroenterol J, 4, pp.380~387 (2016)
147. Mori H, "Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for Helicobacter pylori strains containing the gyrA mutation", Helicobacter, 21, pp.286~294 (2016)
148. Liou JM, "Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori : a randomized trial", Am J Gastroenterol, 111, pp.381~387 (2016)
149. Chuah SK, "A randomized control trial comparing 2 levofloxacin-containing second-line therapies for Helicobacter pylori eradication", Medicine (Baltimore), 95, pp.e3586~ (2016)
150. Chen Q, "Rescue therapy for Helicobacter pylori eradication : a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy", Am J Gastroenterol, 111, pp.1736~1742 (2016)
151. Yang JC, "High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection", Clin Gastroenterol Hepatol, 13, pp.895~905 (2015)
152. Mansour-Ghanaei F, "Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication", World J Gastroenterol, 21, pp.661~666 (2015)
153. Jheng GH, "Comparison of secondline quadruple therapies with or without bismuth for Helicobacter pylori infection", Biomed Res Int, 2015, pp.163960~ (2015)
154. Cao Z, "Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures : a randomized clinical trial", Scand J Gastroenterol, 50, pp.1185~1190 (2015)
155. Lim HC, "Rifabutinbased high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori", Helicobacter, 19, pp.455~461 (2014)
156. Ierardi E, "Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment : comparison between two tetracyclinebased regimens", J Gastrointestin Liver Dis, 23, pp.367~370 (2014)
157. Murakami K, "Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan", J Gastroenterol, 48, pp.1128~1135 (2013)
158. 문지윤, "Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea", Gut and Liver, 7(4), pp.406~410 (2013), 거트앤리버 소화기연관학회협의회
159. Kuo CH, "Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy : a randomized controlled trial", J Antimicrob Chemother, 68, pp.222~228 (2013)
160. Calhan T, "Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori : a pilot study", Helicobacter, 18, pp.378~383 (2013)
161. 윤재훈, "Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication", Gut and Liver, 6(4), pp.434~439 (2012), 거트앤리버 소화기연관학회협의회
162. Chuah SK, "The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin", amoxicillin, Helicobacter, pp.2012, 17[DOI]
163. Chuah SK, "Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori", Helicobacter, 17, pp.216~223 (2012)
164. Wu DC, "Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies", Medicine(Baltimore), 90, pp.180~185 (2011)
165. Hu TH, "Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori", Am J Med Sci, 342, pp.177~181 (2011)
166. Gu LY, "Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients : a randomized pilot study", Helicobacter, 16, pp.284~288 (2011)
167. Chung JW, "Second-line Helicobacter pylori eradication : a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy", Helicobacter, 16, pp.289~294 (2011)
168. Minakari M, "A randomized controlled trial : efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection", Helicobacter, 15, pp.154~159 (2010)
169. Lee BH, "Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection : effect of treatment duration and antibiotic resistance on the eradication rate in Korea", Helicobacter, 15, pp.38~45 (2010)
170. Kuo CH, "Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy", Helicobacter, 15, pp.265~272 (2010)
171. Ueki N, "Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure", Helicobacter, 14, pp.91~99 (2009)
172. Kuo CH, "Efficacy of levofloxacinbased rescue therapy for Helicobacter pylori infection after standard triple therapy : a randomized controlled trial", J Antimicrob Chemother, 63, pp.1017~1024 (2009)
173. Karatapanis S, "Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection", Ann Gastroenterol, 22, pp.263~267 (2009)
174. Di Caro S, "Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication", Dig Liver Dis, 41, pp.480~485 (2009)
175. Bago J, "Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy : a randomized controlled trial", Wien Klin Wochenschr, 121, pp.47~52 (2009)
176. Uygun A, "Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy", J Gastroenterol Hepatol, 23, pp.42~45 (2008)
177. Sanches B, "Failure of Helicobacter pylori treatment after regimes containing clarithromycin : new practical therapeutic options", Helicobacter, 13, pp.572~576 (2008)
178. Nishizawa T, "Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication", J Gastroenterol Hepatol, 23(Suppl 2), pp.S167~S170 (2008)
179. 정해선, "Helicobacter pylori 이차 제균에서 Levofloxacin 포함 삼제요법의 효과", 대한소화기학회지, 51(5), pp.285~290 (2008), 대한소화기학회
180. Gisbert JP, "Systematic review and meta-analysis : levofloxacin-based rescue regimens after Helicobacter pylori treatment failure", Aliment Pharmacol Ther, 23, pp.35~44 (2006)
181. Saad RJ, "Levofloxacinbased triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection : a metaanalysis", Am J Gastroenterol, 101, pp.488~496 (2006)
182. 안병락, "Antibiotic Resistance in Helicobacter pylori Strains and its Effect on H. pylori Eradication Rates in a Single Center in Korea", Annals of Laboratory Medicine, 33(6), pp.415~419 (2013), 대한진단검사의학회
183. Kim JM, "Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients", J Antimicrob Chemother, 56, pp.965~967 (2005)
184. Graham DY, "Rational Helicobacter pylori therapy : evidence-based medicine rather than medicinebased evidence", Clin Gastroenterol Hepatol, 12, pp.177~186 (2014)
185. Marin AC, "A review of rescue regimens after clarithromycin-containing triple therapy failure(for Helicobacter pylori eradication)", Expert Opin Pharmacother, 14, pp.843~861 (2013)
186. Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
187. Liou JM, "Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection", Gastroenterology, 155, pp.1109~1119 (2018)
188. Gisbert JP, "Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection", Aliment Pharmacol Ther, 35, pp.1484~1485 (2012)
189. 임주현, "Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease", Gut and Liver, 11(2), pp.226~231 (2017), 거트앤리버 소화기연관학회협의회
190. Gisbert JP, "Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments", Dig Liver Dis, 47, pp.108~113 (2015)
191. Kang KK, "Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea", World J Gastroenterol, 20, pp.6932~6938 (2014)
192. Gisbert JP, "Helicobacter pylori second-line rescue therapy with levofloxacin-and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments", Aliment Pharmacol Ther, 41, pp.768~775 (2015)
193. Hsu PI, "Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures", Eur J Clin Invest, 38, pp.404~409 (2008)
194. Yee YK, "Clinical trial : levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection", Aliment Pharmacol Ther, 26, pp.1063~1067 (2007)
195. Gisbert JP, "Review article : rifabutin in the treatment of refractory Helicobacter pylori infection", Aliment Pharmacol Ther, 35, pp.209~221 (2012)
196. Navarro-Jarabo JM, "Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection", BMC Gastroenterol, 7, pp.31~ (2007)
197. Miehlke S, "Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin", Aliment Pharmacol Ther, 24, pp.395~403 (2006)
198. Perri F, "Randomized study of two"rescue"therapies for Helicobacter pylori-infected patients after failure of standard triple therapies", Am J Gastroenterol, 96, pp.58~62 (2001)
199. Miehlke S, "A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin", Helicobacter, 8, pp.310~319 (2003)
200. Liou JM, "Sequential versus triple therapy for the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial", Lancet, 381, pp.205~213 (2013)
201. Correa P, "Chemoprevention of gastric dysplasia : randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy", J Natl Cancer Inst, 92, pp.1881~1888 (2000)
202. Leung WK, "Factors predicting progression of gastric intestinal metaplasia : results of a randomised trial on Helicobacter pylori eradication", Gut, 53, pp.1244~1249 (2004)
203. Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
204. Saito D, "Impact of H-pylori eradication on gastric cancer prevention : endoscopic results of the Japanese intervention trial(JITHP-study) : a randomized multi-center trial", Gastroenterology, 128, pp.A4~ (2005)
205. Wong BC, "Effects of selective COX-2inhibitor and Helicobacter pylori eradication on precancerous gastric lesions", Gut, 61, pp.812~818 (2012)
206. Songür Y, "Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment", Am J Med Sci, 338, pp.50~53 (2009)
207. Sapmaz F, "A noninferiority study : modified dual therapy consisting higher doses of rabeprazole is as successful as standard quadruple therapy in eradication of Helicobacter pylori", Am J Ther, 24, pp.e393~ (2017)

관련 논문AI추천